Referencias: 1. Wynzora® Ficha Técnica. Agencia Española de Medicamentos y Productos Sanitarios. Centro de información del Medicamento. Disponible en: https://cima.aemps.es/cima/dochtml/ft/86088/FT_86088.html. 2. Praestegaard, et al. T. Phase 3 Trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. SKIN The Journal of Cutaneous Medicine, 2020; 4(5): s6. 3. Stein Gold L et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. 18. Torres T., et al. Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review. Dermatol Ther (Heidelb) (2023) 13:2153–2169
Referencias: 3. Stein Gold L et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. 5. Armstrong AW, et al. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/ betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21(3):242-248. 6. Praestegaard M, et al. Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application. Dermatol Ther (Heidelb). 2022;10.1007/s13555-022-00794-y. 7. Stein Gold L, Green LJ, Dhawan S, et al. Calcipotriene and betamethasone dipropionate cream combines high efficacy, favorable safety, and treatment preference in a single product for topical treatment of psoriasis. Presented at ODAC Virtual Congress; 14-17 January: 2021. 8. Pinter A, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. JEADV 2022; 36, 228–236.
Referencias: 9. Menter A, et al. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. Skinmed. 2017;15(2):119-24. 10. Kaufmann R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatol Basel Switz. 2002;205(4):389-93 11. Papp KA, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48-54. 12. Jemec GBE, et al. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol JEADV. 2011;25(1):27-32
Referencias: 13. Guilà T, García N, Guiró P, et al. Sensory properties analysis of the main pharmaceutical forms used in the topical treatment of plaque psoriasis. P2323 presented at 32nd European Academy of Dermatology and Venereology Congress. Berlin, 11 14 October 2023. 14. Curcio A, Kontzias C, Gorodokin B, Feldman S, Kircik L. Patient Preferences in Topical Psoriasis Treatment. J Drugs Dermatol 2023;22(4):326-32. 15. Kircik LH, Draelos ZD, Glick B, Green L, Burgess C. Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis. J Drugs Dermatol. 2024;23:607–11
Referencias: 3. Stein Gold L et al. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021 Apr 1;20(4):420-425. 4. Bewley A, et al. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. J Dermatolog Treat 2022;1-26. doi: 10.1080/09546634.2022.2116924. 5. Armstrong AW, et al. Pooled analysis demonstrating superior patient- reported psoriasis treatment outcomes for calcipotriene/ betamethasone dipropionate cream versus suspension/gel. J Drugs Dermatol. 2022;21(3):242-248. 8. Pinter A, et al. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. JEADV 2022; 36, 228–236. 13. Guilà T, García N, Guiró P, et al. Sensory properties analysis of the main pharmaceutical forms used in the topical treatment of plaque psoriasis. P2323 presented at 32nd European Academy of Dermatology and Venereology Congress. Berlin, 11 14 October 2023. 16. López Estebaranz JL, et al. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. Journal of Dermatological Treatment 2024; 35:1, 2357618, DOI: 10.1080/09546634.2024.2357618 17. Halioua B., et al. A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol. 2023;00:1–3.
Wynzora® Ficha Técnica. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/86088/86088_ft.pdf.
Con receta médica. Financiado por el SNS con aportación reducida.
Wynzora® 50 microgramos/g + 0,5 mg/g crema, 1 tubo de 60 g. PVL 28,63 €; PVP IVA: 44,69 €.
Wynzora® 50 microgramos/g + 0,5 mg/g crema, 2 tubos de 60 g. PVL 57,26 €; PVP IVA: 89,39 €.
Fecha de elaboración del material: Septiembre 2024
HQ-WYN-2400024
